TABLE 1.
Patient demographics and clinical characteristics.
| HNCa | HCb | Combinedc | HNC HPV+d | HNC HPV−e | Combinedf | |
| Patient count (Male/Female) | 30 (22/8) | 20 (5/15) | 50 (27/23) | 16 (12/4) | 7 (5/2) | 23 (17/6) |
| Antibiotic treatment (Yes/No) | 11/19 | 0/20 | 11/39 | 4/12 | 4/3 | 8/15 |
| Primary cancer site | ||||||
| Base of tongue | 4 | 4 | 4 | 0 | 4 | |
| Nasopharynx | 2 | 2 | 1 | 1 | 2 | |
| Oral cavity | 1 | 1 | 0 | 1 | 1 | |
| Oropharynx | 1 | 1 | 1 | 0 | 1 | |
| Supraglottis | 1 | 1 | 0 | 1 | 1 | |
| Tongue | 1 | 1 | 0 | 1 | 1 | |
| Tonsil | 8 | 8 | 8 | 0 | 8 | |
| Unknown | 5 | 5 | 2 | 3 | 5 | |
| Age: | ||||||
| Median | 55 | 55 | 55 | 54 | 61 | 54 |
| Mean | 54 | 52.7 | 54 | 54 | 51 | 53 |
| Std Dev | 12.02 | 15.29 | 12.93 | 6.47 | 20.29 | 11.93 |
| Range | 23–75 | 24–84 | 23–84 | 40–68 | 23–75 | 23–75 |
| Ethnicity count | ||||||
| M: Caucasian/African American | 22/0 | 5/0 | 27/0 | 12/0 | 5/0 | 17/0 |
| F: Caucasian/African American | 7/1 | 13/2 | 20/3 | 3/1 | 2/0 | 5/1 |
| Whole mouth average PD | 2.28 (2.03–2.52) | 2.09 (1.78–2.40) | 2.26 (2.06–2.46) | |||
| Whole mouth average CAL | 1.74 (1.42–2.07) | 1.64 (1.02–2.26) | 1.73 (1.46–2.01) | |||
| Sample combinationsg | ||||||
| BPST | 120 | 80 | 200 | 64 | 28 | 92 |
| BST | 120 | 72 | 192 | 54 | 30 | 84 |
| PST | 105 | 69 | 174 | 54 | 21 | 75 |
| BPS | 93 | 63 | 156 |
aHead and neck cancer (HNC) patient group (primary cancer sites: base of tongue = 4; nasopharynx = 2; oral cavity = 1; oropharynx = 1; supraglottis = 1; tongue = 1; tonsil = 8; unknown = 5).
bHealthy control (HC) subject group.
cHNC and HC patient groups combined.
dHNC human papillomavirus positive (HPV+) patient group (primary cancer sites (N = 16); base of tongue = 4; nasopharynx = 1; oral cavity = 0; oropharynx = 1; supraglottis = 0; tongue = 0; tonsil = 8; unknown = 2).
eHNC human papillomavirus negative (HPV–) patient group (primary cancer sites (N = 7); base of tongue = 0; nasopharynx = 1; oral cavity = 1; oropharynx = 0; supraglottis = 1; tongue = 1; tonsil = 0; unknown = 3).
fHNC HPV+ and HPV– patient groups combined.
gNumber of samples for site combinations including B (buccal), P (plaque), S (saliva), and/or T (tongue).
PD, probing depth; CAL, clinical attachment loss; Std Dev, standard deviation. PD and CAL are shown as the average with 95% confidence intervals in parentheses. Mann–Whitney U-tests comparing whole mouth average PD and whole mouth average CAL separately for HPV+ vs. HPV– patient groups were not found to be significantly different (p > 0.05).